<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND AND PURPOSE: Measurement of natriuretic <z:chebi fb="7" ids="16670">peptides</z:chebi> provides prognostic information in various patient populations </plain></SENT>
<SENT sid="1" pm="."><plain>The prognostic value of natriuretic <z:chebi fb="7" ids="16670">peptides</z:chebi> among patients with <z:hpo ids='HP_0011009'>acute</z:hpo> <z:hpo ids='HP_0001297'>stroke</z:hpo> is not known, although elevated <z:chebi fb="7" ids="16670">peptide</z:chebi> levels have been observed </plain></SENT>
<SENT sid="2" pm="."><plain>METHODS: A series of 51 patients (mean age, 68+/-11 years) with first-ever <z:hpo ids='HP_0002140'>ischemic stroke</z:hpo> underwent a comprehensive clinical examination and measurements of plasma atrial natriuretic <z:chebi fb="7" ids="16670">peptides</z:chebi> (N-ANP) and brain natriuretic <z:chebi fb="7" ids="16670">peptides</z:chebi> (N-BNP) in the <z:hpo ids='HP_0011009'>acute</z:hpo> phase of <z:hpo ids='HP_0001297'>stroke</z:hpo> </plain></SENT>
<SENT sid="3" pm="."><plain>The patients were followed-up for 44+/-21 months </plain></SENT>
<SENT sid="4" pm="."><plain>Risk factors for <z:hpo ids='HP_0000001'>all</z:hpo>-cause mortality were assessed </plain></SENT>
<SENT sid="5" pm="."><plain>Control populations, matched for gender and age, consisted of 51 patients with <z:hpo ids='HP_0011009'>acute</z:hpo> <z:hpo ids='HP_0001658'>myocardial infarction</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AMI</z:e>) and 25 healthy subjects </plain></SENT>
<SENT sid="6" pm="."><plain>RESULTS: Plasma concentrations of N-ANP (mean+/-SD, 988+/-993 pmol/L) and N-BNP (751+/-1608 pmol/L) in the <z:hpo ids='HP_0001297'>stroke</z:hpo> patients were at the same level as those in the <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AMI</z:e> patients (NS for both), but significantly higher than those of the healthy subjects (358+/-103 pmol/L, P&lt;0.001 and 54+/-26 pmol/L, P&lt;0.01, respectively) </plain></SENT>
<SENT sid="7" pm="."><plain>Elevated levels of N-ANP and N-BNP predicted mortality after <z:hpo ids='HP_0001297'>stroke</z:hpo> (risk ratio [RR] 4.3, P&lt;0.01 and RR 3.9, P&lt;0.01, respectively) and after <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AMI</z:e> (P&lt;0.05), and remained independent predictors of <z:hpo ids='HP_0011420'>death</z:hpo> after <z:hpo ids='HP_0001297'>stroke</z:hpo> even after adjustment for age, <z:mp ids='MP_0002055'>diabetes</z:mp>, <z:hpo ids='HP_0001677'>coronary artery disease</z:hpo>, and medication (RR 3.9, P&lt;0.05 and RR 3.7, P&lt;0.05, respectively) </plain></SENT>
<SENT sid="8" pm="."><plain>CONCLUSIONS: Plasma levels of natriuretic <z:chebi fb="7" ids="16670">peptides</z:chebi> are elevated in the <z:hpo ids='HP_0011009'>acute</z:hpo> phase of <z:hpo ids='HP_0001297'>stroke</z:hpo> and predict poststroke mortality </plain></SENT>
</text></document>